InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Reumuth Mary, Chief Financial Officer. Director active across 2 companies, notably Kala Pharmaceuticals, Inc.. In total, 15 filings have been published. Split: 0 buy · 10 sells. Total volume traded: €90k. History available since 28 June 2021. The latest transaction was filed on 6 January 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
10,100 shares0Common StockSEC:0001415889-25-001059:0
4,163 shares@ US$4.7564.8% of flowCommon StockSEC:0001415889-24-018375:0
1,786 shares@ US$6.0935.2% of flowCommon StockSEC:0001415889-24-015224:0
4,600 shares0Common StockSEC:0001415889-24-000767:0
36,144 shares0Common StockSEC:0001415889-23-010285:0
14,736 sharesCommon StockSEC:0001415889-23-009136:0
9,525 shares0Common StockSEC:0001415889-23-000639:0
194 shares@ US$6.512.0% of flowCommon StockSEC:0001415889-22-010880:0
2,613 shares@ US$0.370.0059% mcap1.5% of flowCommon StockSEC:0001415889-22-007062:0
2,850 shares@ US$1.305.3% of flowCommon StockSEC:0001415889-22-000405
2,850 shares@ US$1.300.021% mcap5.4% of flowCommon StockSEC:0001415889-22-000405:0
9,449 shares@ US$1.800.095% mcap24.2% of flowCommon StockSEC:0001415889-21-005012:0
9,449 shares@ US$1.8023.7% of flowCommon StockSEC:0001415889-21-005012
2,452 shares@ US$5.7719.2% of flowCommon StockSEC:0001415889-21-003259
2,452 shares@ US$5.770.077% mcap19.6% of flowCommon StockSEC:0001415889-21-003259:0
15 of 15 declarations
About Reumuth Mary
Reumuth Mary is the CHIEF FINANCIAL OFFICER of Kala Pharmaceuticals, Inc. She is responsible for the financial management of the company, including financial planning and analysis. Mary plays a key role in developing financial strategies that support Kala Pharmaceuticals' growth and profitability. Her expertise in finance is essential to ensure the company's financial health.
